Direct Switch Without Taper is Generally Acceptable
Yes, you can discontinue aripiprazole 5 mg and start quetiapine 25 mg without tapering, as both doses are low and the clinical risk of withdrawal or rebound symptoms is minimal at these dosages.
Rationale for Direct Switch
Low Dose Considerations
The aripiprazole dose of 5 mg is at the lower end of the therapeutic range. According to FDA labeling, aripiprazole is typically dosed at 10-15 mg/day for therapeutic effect 1. At 5 mg, you're using a subtherapeutic dose, likely for sedation or augmentation rather than primary antipsychotic effect.
The quetiapine dose of 25 mg is also subtherapeutic for psychiatric indications. Guidelines indicate quetiapine starting doses of 25 mg with titration to therapeutic ranges of 150-750 mg/day 2. At 25 mg, this is clearly being used off-label for sleep rather than antipsychotic effect.
Withdrawal Risk Assessment
Aripiprazole has a long half-life (75 hours) and partial agonist properties at dopamine receptors, which inherently reduces withdrawal risk. The FDA label notes that while immediate discontinuation may be acceptable for some patients, gradual discontinuation may be appropriate for others, but provides no specific tapering requirement 1. Research confirms that abrupt switches from aripiprazole do not produce significant clinical consequences 3.
At 5 mg, the receptor occupancy is minimal, further reducing any withdrawal concerns. General psychotropic medication guidelines recommend tapering to avoid withdrawal symptoms or rebound worsening 4, but this primarily applies to:
- Benzodiazepines
- SSRIs (particularly paroxetine, fluvoxamine, sertraline) 5
- Antipsychotics for tics or lithium for mania 4
Cross-Titration Not Required
The quetiapine 25 mg dose provides immediate sedating effects that can substitute for any sleep benefit from the aripiprazole. Quetiapine is noted as sedating even at low doses 2, and research shows it improves sleep quality at 50 mg doses 6. The 25 mg dose, while lower, still provides sedative effects that can bridge any transition period.
Practical Implementation
Switching Strategy
- Stop aripiprazole 5 mg at bedtime on day 1
- Start quetiapine 25 mg at bedtime on day 1 (same evening)
- No overlap period needed
- No gradual cross-titration required
Monitoring Plan
Monitor for the following over 2-4 weeks:
Unlikely withdrawal symptoms from aripiprazole:
- Insomnia (though quetiapine should prevent this)
- Anxiety or agitation
- Headache
- Nausea
Expected quetiapine effects:
- Sedation (desired at bedtime)
- Orthostatic hypotension (check blood pressure if dizziness occurs)
- Morning grogginess
- Dry mouth
Red flags requiring immediate attention:
- Severe agitation or psychotic symptoms (suggests underlying condition needs higher antipsychotic dosing)
- Falls or significant orthostatic symptoms
- Excessive daytime sedation
Important Caveats
Clinical Context Matters
This recommendation assumes:
- The 5 mg aripiprazole was used for sleep/sedation or mild augmentation, not primary treatment of psychosis or mania
- No history of severe withdrawal reactions from antipsychotic discontinuation
- The patient is clinically stable
If aripiprazole was treating active psychotic symptoms or mania, this switch is inappropriate - quetiapine 25 mg is not therapeutic for these conditions and would require doses of 150-800 mg/day 2.
Age and Frailty Considerations
In elderly or frail patients, even these low doses warrant caution. Guidelines recommend lower starting doses in older patients for both medications 2, 7, 2. The direct switch remains acceptable, but monitoring for orthostatic hypotension, falls, and cognitive effects becomes more critical.
Alternative if Concerned
If you remain concerned about withdrawal despite the low dose, the most conservative approach would be:
- Continue aripiprazole 5 mg for 3-7 days while starting quetiapine 25 mg
- Then stop aripiprazole
However, this overlap is not necessary based on the pharmacology and doses involved, and adds unnecessary polypharmacy exposure.